>>OTS186935 hydrochloride

OTS186935 hydrochloride

Catalog No.GC60279

OTS186935 염산염은 IC50이 6.49nM인 강력한 단백질 메틸트랜스퍼라제 SUV39H2 억제제입니다. OTS186935 염산염은 검출 가능한 독성 없이 마우스 이종이식 모델에서 종양 성장의 상당한 억제를 보여줍니다. OTS193320 염산염은 암세포에서 γ-H2AX의 생산을 조절합니다.

Products are for research use only. Not for human use. We do not sell to patients.

OTS186935 hydrochloride Chemical Structure

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$320.00
재고 있음
5mg
US$278.00
재고 있음
10mg
US$464.00
재고 있음
50mg
US$1,298.00
재고 있음
100mg
US$1,808.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

OTS186935 hydrochloride is a potent protein methyltransferase SUV39H2 inhibitor with an IC50 of 6.49 nM. OTS186935 hydrochloride shows significant inhibition of tumor growth in mouse xenograft models without any detectable toxicity. OTS193320 hydrochloride regulates the production of γ-H2AX in cancer cells[1].

OTS186935 hydrochloride inhibits A549 cell growth with an IC50 of 0.67 μM[1].

OTS186935 hydrochloride (10 mg/kg or 25 mg/kg; intravenously; once daily for 14 days) exhibits growth suppressive effects in human cancer cell line derived xenograft models[1]. Animal Model: Female NOD.CB17-Prkdcscid/J mice (bearing MDA-MB-231 cells )[1]

[1]. Vougiouklakis T, et al. Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX. Oncotarget. 2018 Aug 7;9(61):31820-31831.

리뷰

Review for OTS186935 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for OTS186935 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.